Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. reports developments in sleep health, respiratory care and home healthcare technology. The company supplies sleep apnea and breathing-care devices, including CPAP platforms such as AirSense 11, and supports them with cloud-connected software, AI-enabled digital health tools and patient data applications used in out-of-hospital care.
Recurring updates include quarterly operating results, demand trends for sleep and respiratory care products, FDA-cleared digital medical devices such as Smart Comfort, supply-chain and distribution capacity, shareholder returns, executive leadership changes and investor conference presentations. ResMed’s announcements also reflect its NYSE-listed common stock and ASX-traded presence.
ResMed (NYSE: RMD) plans to release its financial and operational results for Q3 of fiscal year 2022 on April 28, 2022, post-market close. Following this, management will host a webcast to discuss the results and other relevant information. The webcast will be available internationally, with details for various time zones provided. A replay of the earnings call will be accessible approximately two hours post-webcast. ResMed focuses on innovative solutions for chronic diseases, impacting healthcare quality and costs.
ResMed (NYSE: RMD) announces participation of CEO Mick Farrell in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 22, 2022, at 1:30 p.m. EDT. The event will be available via webcast, with a replay accessible within an hour after the live session. ResMed focuses on innovative healthcare solutions for chronic diseases, supporting better patient care through digital health technologies and cloud-connected devices, operating in over 140 countries.
Summary not available.
ResMed (NYSE: RMD) announces that Rob Douglas, president and COO, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 1:20 p.m. EDT. The presentation will be accessible via a live webcast, with a replay available for viewing through June 13, 2022. ResMed specializes in developing innovative solutions for chronic diseases like sleep apnea and COPD, focusing on digital health technologies and cloud-connected medical devices that enhance patient care and reduce healthcare costs globally.
ResMed (NYSE: RMD) announces that CEO Mick Farrell will participate in a virtual fireside chat at the Citi Healthcare Conference on February 23, 2022, at 12:30 p.m. EST. This event will be accessible via webcast, with a replay available for 24 hours post-event until February 23, 2023. ResMed specializes in innovative solutions for chronic diseases, particularly focusing on digital health technologies and cloud-connected medical devices aimed at enhancing patient care and reducing healthcare costs globally.
ResMed has appointed Urvashi Tyagi as its new Chief Technology Officer effective February 1, 2022. With over 25 years of experience from companies like ADP, American Express, and Amazon, Tyagi will spearhead ResMed's digital health innovation and cloud technologies. Bobby Ghoshal, the former CTO, will now focus entirely on leading the company’s SaaS business. CEO Mick Farrell emphasized Tyagi's leadership skills and experience as pivotal for enhancing ResMed's digital ecosystem aimed at improving the lives of 250 million people by 2025.
ResMed (NYSE: RMD) reported a 12% year-over-year revenue increase, reaching $894.9 million for Q2 2022. Operating profit also rose by 12%, while non-GAAP operating profit saw a 5% growth. Diluted earnings per share climbed to $1.37, and non-GAAP diluted earnings per share hit $1.47. Despite challenges in supply chains, ResMed managed to meet high demand for sleep and respiratory care products. The company announces a quarterly cash dividend of $0.42 per share, payable on March 17, 2022, and continues its goal to improve life quality for 250 million people by 2025.
ResMed (NYSE: RMD) announced it will release its financial and operational results for Q2 fiscal year 2022 on January 27, 2022, post-market. This will be followed by a management webcast to discuss the results and other relevant information. Key details include the earnings call scheduled at 1:30 p.m. PST / 4:30 p.m. EST, with international times listed for London and Sydney. A replay of the webcast will be available approximately two hours after the event.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. EST via webcast. This conference offers an opportunity for investors to hear about ResMed’s innovative solutions for chronic diseases and its digital health technologies. Access to the live webcast and the replay will be available through their investor relations website. The presentation aims to highlight how ResMed is improving healthcare quality and reducing costs globally.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022, at 4:00 p.m. EST. The event will be available via live webcast, with a replay accessible for one year after the event. ResMed focuses on innovative healthcare solutions that treat chronic diseases, enhancing quality of life and reducing healthcare costs across more than 140 countries.